NK cell therapy for high-risk neuroblastoma in children
Part of Cancer clinical trials.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or younger, any gender.
- Diagnosed with high-risk neuroblastoma that has come back or not responded to treatment.
- Must have had previous treatments like surgery, chemo, and possibly radiation or stem cell transplant.
- General health and blood counts must be within certain limits (e.g., enough white blood cells, platelets, etc.).
- No major heart, lung, or bleeding problems, and no active infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a stem cell transplant from a donor can help children with high-risk neuroblastoma. It aims to replace damaged bone marrow with healthy cells to fight the cancer.
This trial tests a new type of immune therapy (CAR T-cells) that is engineered to find and attack neuroblastoma cells by targeting specific markers (GD2, PSMA, and CD276) on the cancer cells. It is for patients whose cancer has not responded to standard treatments and who are healthy enough to receive this experimental cell therapy.
This trial tests a new treatment combining your child's own immune cells (NK cells) with an antibody that targets neuroblastoma cells. It is for children who have just finished standard treatment or whose cancer has come back or not responded, and aims to improve outcomes.
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.